IL-23 Inhibitors Appear Safe in Psoriasis With Cancer
A study found low rates of cancer recurrence, progression, or new malignancy among patients with psoriasis and prior neoplasia receiving interleukin-23 (IL-23) inhibitors.
METHODOLOGY:
Researchers conducted a retrospective, observational, multicenter study across 16 dermatology centers in Italy, which included 198 adults (39.9% women; mean age, 65.5 years) with moderate-to-severe plaque psoriasis and a personal history of cancer.
Participants were being treated with anti-IL-23 agents (guselkumab, risankizumab, or tildrakizumab); 33.8% had a history of malignancy within the past 5 years, and 66.2% had been diagnosed with cancer before that time.
Primary endpoints were neoplasia progression or recurrence or new neoplastic events, while secondary outcomes evaluated potential risk factors.
TAKEAWAY:
Progression or recurrence of existing neoplasia was reported in six patients (3.0%) during the study period; bladder cancer was the most common (50%), followed by individual cases of breast cancer, leiomyosarcoma, and pleural mesothelioma. No significant difference was seen between the therapies.
Additionally, six patients (3.0%) developed new cancers during IL-23 treatment, including one case each of breast cancer, gastric cancer, cutaneous melanoma, renal cancer, uterine squamous cell carcinoma, and hepatic cholangiocarcinoma, with only two cases leading to treatment discontinuation.
Despite a higher occurrence of new cancer development in patients receiving risankizumab (four patients, 67%) compared with guselkumab (one patient, 17%) and tildrakizumab (one patient, 17%), the difference was not statistically significant.
No significant associations were found between the incidence of neoplastic progression or recurrence, or the development of a new neoplasia, with comorbidities or previous treatments.
IN PRACTICE:
'To the best of our knowledge, our real-life experience is the largest study investigating the use of anti-IL-23 agents and the risk of cancer recurrence, progression, and development in patients with a history of cancer,' the study authors wrote. 'Despite the reassuring data, larger studies are needed to confirm these results.'
SOURCE:
The study was led by Francesca Satolli, Dermatology Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy, and was published online on June 16 in the Clinical and Experimental Dermatology.
LIMITATIONS:
Limitations included retrospective design, limited sample size, lack of a control group, and heterogeneity in cancer types and stages.
DISCLOSURES:
Almirall provided support for manuscript writing costs. The authors declared having no conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Kennedy's move to cancel preventive health panel meeting raises alarm
If you've ever been given a free or low-cost test for lung, breast, colon or cervical cancer which caught a tumor, it's likely due to a panel of 16 doctors and public health experts who reviewed the evidence and determined that a screening could save your life. That's why anxiety is growing after Health and Human Services Secretary Robert F. Kennedy Jr. abruptly postponed a meeting this week with the highly influential United States Preventive Services Task Force, a group of 16 independent volunteers that advise the agency about preventative health services and screenings, including mammograms, HIV prevention medications, recommending support for new moms to breastfeed and lifestyle interventions for heart disease. Health insurance plans are required to cover the task force's recommendations under the Affordable Care Act. The meeting, scheduled for July 10, was postponed without explanation. In an emailed statement, Andrew Nixon, an HHS spokesperson, declined to say why the meeting was canceled or whether it would be rescheduled. He did not respond to a follow-up request for comment. An HHS notice sent Monday afternoon to task force members said the agency 'looks forward to engaging with the task force to promote the health and well-being of the American people,' according to two people familiar with the task force meeting. Task force members were not given a reason for the canceled meeting or whether it would be rescheduled, said the two people interviewed, who spoke on the condition of anonymity for fear of retribution. Many task force members, however, fear Kennedy's move could signal that he's gearing up to fire them and install new members, as he did with a separate advisory committee, known as the Advisory Committee on Immunization Practices (ACIP), the sources said. Last month, Kennedy fired all 17 members of ACIP — which makes recommendations to the Centers for Disease Control and Prevention on vaccines, including for children — and replaced them with eight new members. The new panel includes well-known vaccine critics. 'If you look at how things played out with ACIP, this could be a warning signal,' one of the people said. The United States Preventive Services Task Force is a lesser known group that was first convened in 1984 during the Reagan administration. It includes physicians, nurses, pediatricians and public health experts. The task force plays an important role because the ACA , more commonly known as Obamacare, mandates that most private insurers provide the services that the group recommends to patients at no cost. The task force makes its recommendations using a grading scale. Under federal law, services that get an A or B grade but must be covered by insurance plans at no cost to patients. The advisory group has been subject to outrage for its past decisions, including from conservative groups over an 'A' recommendation to cover the HIV prevention pill, known as PrEP. Its controversial decision against routine blood test screening for prostate cancer in 2008 has been linked to rising rates of advanced cases of the disease. The task force currently advises against PSA-screening for older men, saying that men ages 55 to 69 should talk with their doctors about the benefits and harms. The group usually updates its recommendations every five years after reviewing the latest science on preventive care. For example, in 2021, the task force updated its guidance on heart attack prevention, saying most adults shouldn't take aspirin to prevent a first heart attack or stroke. Other recommendations from the task force include that all women begin breast cancer screening every other year starting at the age of 40, down from age 50. It also recommended that children and teens age 8 and up get screened for anxiety. Both have 'B' recommendations. The canceled meeting was set to discuss cardiovascular disease and prevention in adults and children, the people said. 'This institution proves vital,' said Arthur Caplan, the head of the Division of Medical Ethics at NYU Langone Medical Center in New York City. 'The task force provides one of the few independent evidence-based assessments of what ought to be covered, especially in the area of prevention, which Kennedy has made a priority.' 'Postponing the meeting makes me very nervous,' Caplan added. As health secretary, Kennedy does have the authority to remove and appoint new members of the committee, said Jen Kates, senior vice president and director of the Global Health & HIV Policy Program at KFF, a health policy research group. That authority was actually a factor in the Supreme Court's decision last month to uphold the Affordable Care Act provision that requires insurers to cover certain preventive services for free. The court agreed with the Trump administration that the task force members were 'inferior officers,' Kates said, because their work was directed and supervised by Kennedy. 'The Supreme Court basically ruled that the [health] secretary has the power to appoint members and remove them at will,' Kates said. 'So it basically affirms the argument that the secretary has the ultimate authority over the panel.' It's unclear which areas of health care Kennedy might target by shaking up the panel. PrEP, the HIV prevention pill, is 'one to watch,' Kates said, because the Trump administration has already moved to restrict access to the medication in other countries. Caplan said Kennedy could direct the task force to look into topics he's interested in, such as nutrition or processed foods. Health groups immediately pushed back when news broke that Kennedy postponed the meeting. On Wednesday, a letter signed by more than 100 public health groups — including the American Medical Association and the American Academy of Pediatrics — urged U.S. lawmakers to 'defend the task force's integrity.' The letter was led by AcademyHealth, a group representing health researchers. This article was originally published on
Associated Press
4 hours ago
- Associated Press
Onco-Innovations Signs Agreement with Redwood AI to Advance Discovery and Evaluation of Its PNKP Inhibitor Technology
VANCOUVER, BC / ACCESS Newswire / July 11, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN: A3EKSZ) ('Onco' or the 'Company') is pleased to announce that it has entered into a services agreement with Redwood AI Inc. (Redwood AI). This collaboration marks continued advancement of Onco's mission to accelerate the development of its exclusively-licensed Polynucleotide Kinase Phosphatase (PNKP) Compound (the 'Technology') and to extend its proprietary knowledge through discovery. This proprietary compound aims to target a range of solid tumours by enhancing sensitivity to radiation and DNA-damaging chemotherapies, offering the potential to exploit specific genetic susceptibilities in cancer. Through this agreement with Redwood AI, Onco gains access to Redwood AI's AI-driven chemistry tools that have the potential to unlock critical efficiencies in drug development, thereby carrying the potential to reduce synthesis complexity, refine compound design, and expand the pipeline of viable analogs. This effort is aimed at reinforcing Onco's technical capabilities at a crucial preclinical phase, with the goal of improving scalability, safety, and discovery precision. Under the scope of the agreement, Redwood AI will provide multi-pronged support across synthesis evaluation, cheminformatics, and organ-specific toxicity prediction for the Technology and its structural analogs. This includes independent reviews of third-party chemistry proposals and the use of Redwood's proprietary in-silico modelling tools. In simpler terms, these efforts are intended to deepen Onco's understanding of its Technology by supporting structure-based refinement and mechanistic insight. These efforts are part of Onco's broader strategy to efficiently progress toward First-in-Human studies. Redwood AI is a Vancouver-based artificial intelligence company harnessing artificial intelligence to accelerate drug synthesis and development. Founded by a team with deep roots in chemistry, AI, and drug manufacturing, including origins from Stanford1, Redwood AI is focused on overcoming one of the pharmaceutical industry's most persistent challenges - drug synthesis. By automating a substantial portion of the traditionally manual steps involved in synthesis, Redwood's technology aims to support more accurate, scalable, and cost-effective drug creation, with the goal of helping research teams move from discovery to development faster and with greater efficiency. 'The pace of innovation in cancer therapeutics depends on how quickly we can turn complex data into actionable decisions. Redwood AI's platform has the potential to enable us to explore synthesis strategies, evaluate risks, and optimize compound design with greater speed and precision. This kind of insight not only strengthens our scientific direction but also has the potential to accelerate our timeline towards clinical trials,' stated Thomas O'Shaughnessy, CEO of Onco-Innovations. About Onco-Innovations Limited Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours. ON BEHALF OF ONCO-INNOVATIONS LIMITED, 'Thomas O'Shaughnessy' Chief Executive Officer For more information, please contact: Thomas O'Shaughnessy Chief Executive Officer Tel: + 1 888 261 8055 [email protected] Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as 'will', 'may', 'potential', 'should', 'anticipate', 'expects' and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law. 1 SOURCE: Onco-Innovations Limited press release
Yahoo
5 hours ago
- Yahoo
Aegis Capital Reaffirms Buy on Atai Life Sciences N.V. (ATAI) with $8 Target
Atai Life Sciences N.V. (NASDAQ:ATAI) is among the . Aegis Capital analysts have reaffirmed their Buy rating on Atai Life Sciences N.V. (NASDAQ:ATAI), with an unchanged price target of $8.00, following the favorable Phase 2b results of the BPL-003 treatment for the company's Treatment Resistant Depression (TRD). Around 193 depression patients, who didn't respond to previous treatment, were part of the Phase 2b trial testing three doses: 0.3 mg, 8 mg, and 12 mg. Not only the 8mg but also the 12mg dose showcased statistically significant improvement in an FDA-accepted measurement of depression, with a healthy side-effect profile. A close-up of a medical professional providing advice to a patient struggling with opioid use disorder. The research firm believes these robust results strengthen the company's efforts to proceed to a Phase 3 clinical program, which would result in marketing approval. Going forward, Atai Life Sciences N.V. (NASDAQ:ATAI) plans to schedule a post-Phase 2 meeting with the FDA, with the Phase 3 trial expected to begin only at the end of the upcoming year. Another noteworthy development is the company's recent $50 million private capital raise, which involved the sale of 18,264,840 common shares with 25% warrant coverage at the market price. Moves like these highlight Atai Life Sciences N.V. (NASDAQ:ATAI)'s capacity to raise cash when needed. Atai Life Sciences N.V. (NASDAQ:ATAI) is a German clinical-stage biopharmaceutical company that researches, develops, and markets mental health treatments in the United States, Germany, and Canada. With a market capitalization of $587.639 million, the company is committed to healing mental health disorders. While we acknowledge the potential of ATAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
